An association study between genetic polymorphisms related to lipoprotein-associated phospholipase A2 and coronary heart disease

Experimental and Therapeutic Medicine

Volumn 5, Issue 3, 2013, Pages 742-750

  Xu, Limin ^a   Zhou, Jianqing ^b   Huang, Stephanie ^c   Huang, Yi ^a   Le, Yanping ^a   Jiang, Danjie ^a   Wang, Feiming ^d   Yang, Xi ^b   Xu, Weifeng ^b   Huang, Xiaoyan ^b   Dong, Changzheng ^a   Zhang, Lina ^a   Ye, Meng ^a   Lian, Jiangfang ^b   Duan, Shiwei ^a  

^a NINGBO UNIVERSITY   (China)

^b Lihuili Hospital   (China)

^c UNIVERSITY OF CHICAGO   (United States)

^d Zhejiang Zhenhai Middle School   (China)

Author keywords

CELSR2; Coronary heart disease; Lipoprotein associated phospholipase A2; PLA2G7; Single nucleotide polymorphism; ZNF259

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84873165878     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.911     Document Type: Article

References (42)

1. Epps KC and Wilensky RL: Lp-PLA(2)-a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med 269: 94-106, 2011.
2. Rubinstein A and Izkhakov E: Lipoprotein associated phospholipase A2. Harefuah 150: 136-140, 205, 2011 (In Hebrew).
3. Zheng GH, Chen HY, Xiong SQ and Chu JF: Lipoprotein-associated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis. Mol Biol Rep 38: 4089-4099, 2011.
4. Ballantyne CM, Hoogeveen RC, Bang H, et al: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109: 837-842, 2004.
5. Suchindran S, Rivedal D, Guyton JR, et al: Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet 6: e1000928, 2010.
6. Sandhu MS, Waterworth DM, Debenham SL, et al: LDL-cholesterol concentrations: a genome-wide association study. Lancet 371: 483-491, 2008.
7. Assmann G, Schulte H, von Eckardstein A and Huang Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124: S11-S20, 1996.
8. Gordon T, Castelli WP, Hjortland MC, Kannel WB and DawberTR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707-714, 1977.
9. Lim S, Park YM, Sakuma I and Koh KK: How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol: April 12, 2012 (Epub ahead of print).
10. Sertic J, Skoric B, Lovric J, Bozina T and Reiner Z: Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease? Acta Med Croatica 64: 237-245, 2010 (In Croatian).
11. Thompson A, Gao P, Orfei L, et al: Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375: 1536-1544, 2010.
12. Delgado P, Chacon P, Penalba A, et al: Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients. Cerebrovasc Dis 33: 150-158, 2012.
13. Grallert H, Dupuis J, Bis JC, et al: Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J 33: 238-251, 2012.
14. Higgs ZC, Macafee DA, Braithwaite BD and Maxwell-ArmstrongCA: The Seldinger technique: 50 years on. Lancet 366: 1407-1409, 2005.
15. No authors listed: Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation59: 607-609, 1979.
16. Gabriel S, Ziaugra L and Tabbaa D: SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet Chapter 2: Unit 2.12, 2009.
17. Excoffier L and Lischer HE: Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 10: 564-567, 2010.
18. Sham PC and Curtis D: Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59: 97-105, 1995.
19. Dupont WD and Plummer WD Jr: Power and sample size calculations. A review and computer program. Control Clin Trials 11: 116-128, 1990.
20. Emslie C: Women, men and coronary heart disease: a review of the qualitative literature. J Adv Nurs 51: 382-395, 2005.
21. Gorelick PB: Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol 101: 34F-40F, 2008.
22. Samani NJ, Braund PS, Erdmann J, et al: The novel genetic variant predisposing to coronary artery disease in the region of the PSRC1 and CELSR2 genes on chromosome 1 associates with serum cholesterol. J Mol Med (Berl) 86: 1233-1241, 2008.
23. Zhou L, Ding H, Zhang X, et al: Genetic variants at newly identified lipid loci are associated with coronary heart disease in a Chinese Han population. PLoS One 6: e27481, 2011.
24. Casas JP, Ninio E, Panayiotou A, et al: PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 121: 2284-2293, 2010.
25. Sutton BS, Crosslin DR, Shah SH, et al: Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet 17: 1318-1328, 2008.
26. Li L, Qi L, Lv N, et al: Association between lipoprotein-associated phospholipase A2 gene polymorphism and coronary artery disease in the Chinese Han population. Ann Hum Genet 75: 605-611, 2011.
27. Jang Y, Kim OY, Koh SJ, et al: The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab 91: 3521-3527, 2006.
28. Jang Y, Waterworth D, Lee JE, et al: Carriage of the V279F null allele within the gene encoding Lp-PLA(2) is protective from coronary artery disease in South Korean males. PLoS One 6: e18208, 2011.
29. Willer CJ, Sanna S, Jackson AU, et al: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161-169, 2008.
30. Naj AC, West M, Rich SS, et al: Association of scavenger receptor class B type I polymorphisms with subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Genet 3: 47-52, 2010.
31. Brautbar A, Covarrubias D, Belmont J, et al: Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis 219: 737-742, 2011.
32. Waterworth DM, Ricketts SL, Song K, et al: Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol 30: 2264-2276, 2010.
33. Guo L, Song Z, Li M, et al: Scavenger receptor BI protects against septic death through its role in modulating inflammatory response. J Biol Chem 284: 19826-19834, 2009.
34. Rodriguez-Esparragon F, Rodriguez-Perez JC, Hernandez-TrujilloY, et al: Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. Arterioscler Thromb Vasc Biol 25: 854-860, 2005.
35. Papp AC, Pinsonneault JK, Wang D, et al: Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One 7: e31930, 2012.
36. Schierer A, Been LF, Ralhan S, Wander GS, Aston CE and Sanghera DK: Genetic variation in cholesterol ester transfer protein, serum CETP activity, and coronary artery disease risk in Asian Indian diabetic cohort. Pharmacogenet Genomics 22: 95-104, 2012.
37. Smith EN, Chen W, Kahonen M, et al: Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study. PLoS Genet 6: e1001094, 2010.
38. Borggreve SE, Hillege HL, Wolffenbuttel BH, et al: An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 91: 3382-3388, 2006.
39. Anand SS, Xie C, Pare G, et al: Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study. Circ Cardiovasc Genet 2: 16-25, 2009.
40. Yang KC, Su YN, Shew JY, et al: LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population. J Formos Med Assoc 106: 799-807, 2007.
41. Ahmed W, Ajmal M, Sadeque A, et al: Novel and recurrent LDLR gene mutations in Pakistani hypercholesterolemia patients. Mol Biol Rep 39: 7365-7372, 2012.
42. Slimani A, Jelassi A, Jguirim I, et al: Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Atherosclerosis 222: 158-166, 2012.